3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Multiple Myeloma
3
Leukemia, Myeloid, Acute
2
Colorectal Neoplasms
2
Stomach Neoplasms
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Osteosarcoma
1
Neuroblastoma
1
Lymphoma, T-Cell
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell
1
Lymphoma
1
Leukemia
1
Gliosarcoma
1
Glioblastoma
1
Esophageal Neoplasms
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Burkitt Lymphoma
1
Brain Neoplasms
1
Interventions
Cyclophosphamide
4
Prednisone
3
Lenalidomide
3
fludarabine phosphate
2
etoposide phosphate
2
cobomarsen
2
Whole-Body Irradiation
2
Vorinostat
2
Vincristine
2
Stem Cell Transplantation
2
Nivolumab
2
Melphalan
2
Granulocyte Colony-Stimulating Factor
2
Filgrastim
2
Etoposide
2
Doxorubicin
2
Bortezomib
2
Alemtuzumab
2
tazemetostat
1
sargramostim
1
romidepsin
1
poly ICLC
1
plerixafor
1
pegylated granulocyte colony-stimulating factor, human
1
pegfilgrastim
1
pegaspargase
1
liposomal doxorubicin
1
forodesine
1
fludarabine
1
duvelisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Lymphoma, T-Cell
×
Immunotherapy, Adoptive
×
Clear all
NCT01685606
2022-03-04
273
Brown University
Phase 2
Terminated
6 enrolled
7 charts